UCLA Broad Stem Cell Research Center

Last updated
UCLA Broad Stem Cell Research Center
Established2005 (2005)
Location
  • 610 Charles E Young Dr S, Los Angeles, CA 90095
Members
250 faculty
Director
Thomas A. Rando

The Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA, also known as the UCLA Broad Stem Cell Research Center, is a biomedical research center at the University of California, Los Angeles that focuses on driving groundbreaking stem cell research discoveries from the laboratory to the patient. Founded in 2005, the center is committed to a collaboration of scientific, academic and medical disciplines to revolutionize the treatment of disease through personalized cellular therapies and regenerative medicine. The center's more than 250 faculty members represent the UCLA professional schools as well as the College. Its work is guided by the UCLA's three institutional responsibilities: education, research and service.

Contents

History

In 2005, then-UCLA Chancellor Albert Carnesale launched the center, initially named the Institute for Stem Cell Biology and Medicine, to create and support multidisciplinary teams of UCLA stem cell researchers that would utilize cutting-edge technologies to spearhead the next generation of medicine. [1] [2] Under the leadership of founding director Owen Witte and co-director Judith Gasson, [3] the institute began recruiting internationally renowned scientists to join its membership. In 2006, the institute was awarded its first grant from the California Institute for Regenerative Medicine (CIRM) to launch a program to train the next generation of scientists and clinicians in stem cell research and regenerative medicine. [4]

In 2007, the institute was renamed the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA in recognition of a $20 million gift from The Eli and Edythe Broad Foundation. [5]

In 2014, the center — along with the Sue & Bill Gross Stem Cell Research Center at University of California, Irvine — received an $8-million grant from CIRM to establish a CIRM Alpha Stem Cell Clinic "center of excellence" to conduct clinical trials for investigational stem cell therapies and provide critical resources and expertise in clinical research. [6]  In 2022, the center received an $8-million grant from CIRM to expand the UCLA Alpha Stem Cell Clinic and include a wider cross-section of Los Angeles' diverse population. [7]

Facilities

The UCLA Broad Stem Cell Research Center supports several shared resources, [8] including research cores and infrastructure, that provide UCLA researchers with access to cutting-edge equipment, state-of-the-art facilities and highly trained technical staff.

It also offers a continuum of training opportunities for UCLA undergraduate and graduate students, postdoctoral scholars and clinical fellows as well as undergraduates from California State University, Northridge through a special partnership. This research training provides hands-on experience in the labs of some of the world's top stem cell researchers and serves as a fundamental pathway for education and career development that reflects the center's commitment to train the next generation of stem cell scientists. [9]

Impact

Center researchers have made strides in understanding stem cells and turning discoveries made in the lab into therapies and cures. A more comprehensive view of the center's milestones can be found on their website. [10]

In 2008 — only three years after the center's inception — a group of center scientists led by Kathrin Plath and William Lowry were the first in California to reprogram human skin cells into cells with embryonic stem cell-like properties without using embryos or eggs, impacting disease treatment, tissue engineering and transplantation medicine. [11]

In the years since, center members have also led or are leading clinical trials of stem cell-based or regenerative medicine approaches including:

Related Research Articles

<span class="mw-page-title-main">Gene therapy</span> Medical field

Gene therapy is a medical technology that aims to produce a therapeutic effect through the manipulation of gene expression or through altering the biological properties of living cells.

The California Institute for Regenerative Medicine (CIRM) was created in 2004 after 59% of California voters approved California Proposition 71: the Research and Cures Initiative, which allocated $3 billion to fund stem cell research in California.

Metachromatic leukodystrophy (MLD) is a lysosomal storage disease which is commonly listed in the family of leukodystrophies as well as among the sphingolipidoses as it affects the metabolism of sphingolipids. Leukodystrophies affect the growth and/or development of myelin, the fatty covering which acts as an insulator around nerve fibers throughout the central and peripheral nervous systems. MLD involves cerebroside sulfate accumulation. Metachromatic leukodystrophy, like most enzyme deficiencies, has an autosomal recessive inheritance pattern.

<span class="mw-page-title-main">Regenerative medicine</span> Field of medicine involved in regenerating tissues

Regenerative medicine deals with the "process of replacing, engineering or regenerating human or animal cells, tissues or organs to restore or establish normal function". This field holds the promise of engineering damaged tissues and organs by stimulating the body's own repair mechanisms to functionally heal previously irreparable tissues or organs.

UC San Diego Health is the academic health system of the University of California, San Diego in San Diego, California. It is the only academic health system serving San Diego and has one of three adult Level I trauma centers in the region. In operation since 1966, it comprises three major hospitals: UC San Diego Medical Center in Hillcrest, Jacobs Medical Center in La Jolla, and UC San Diego Health East Campus Medical Center in East County. The La Jolla campus also includes the Moores Cancer Center, Shiley Eye Institute, Sulpizio Cardiovascular Center, and Koman Family Outpatient Pavilion, and the health system also includes several outpatient sites located throughout San Diego County. UC San Diego Health works closely with the university's School of Medicine and Skaggs School of Pharmacy to provide training to medical and pharmacy students and advanced clinical care to patients.

<span class="mw-page-title-main">2004 California Proposition 71</span> California law

Proposition 71 of 2004 is a law enacted by California voters to support stem cell research in the state. It was proposed by means of the initiative process and approved in the 2004 state elections on November 2. The Act amended both the Constitution of California and the Health and Safety Code.

Stem-cell therapy uses stem cells to treat or prevent a disease or condition. As of 2016, the only established therapy using stem cells is hematopoietic stem cell transplantation. This usually takes the form of a bone marrow transplantation, but the cells can also be derived from umbilical cord blood. Research is underway to develop various sources for stem cells as well as to apply stem-cell treatments for neurodegenerative diseases and conditions such as diabetes and heart disease.

<span class="mw-page-title-main">Lentiviral vector in gene therapy</span>

Lentiviral vectors in gene therapy is a method by which genes can be inserted, modified, or deleted in organisms using lentiviruses.

<span class="mw-page-title-main">Jan Nolta</span> American scientist

Jan A. Nolta is an American scientist and the director of the stem cell program at the UC Davis School of Medicine and Institute for Regenerative Cures. She is Scientific Director for the UC Davis Good Manufacturing Practice and editor of the journal Stem Cells. Nolta is known for her work with stem cell-related regenerative medicine. Nolta's current research focuses on treatment of Huntington's disease using mesenchymal stem cells. She was elected a AAAS Fellow in 2013.

<span class="mw-page-title-main">Limbal stem cell</span>

Limbal stem cells, also known as corneal epithelial stem cells, are unipotent stem cells located in the basal epithelial layer of the corneal limbus. They form the border between the cornea and the sclera. Characteristics of limbal stem cells include a slow turnover rate, high proliferative potential, clonogenicity, expression of stem cell markers, as well as the ability to regenerate the entire corneal epithelium. Limbal stem cell proliferation has the role of maintaining the cornea; for example, by replacing cells that are lost via tears. Additionally, these cells also prevent the conjunctival epithelial cells from migrating onto the surface of the cornea.

The stem cell secretome is a collective term for the paracrine soluble factors produced by stem cells and utilized for their inter-cell communication. In addition to inter-cell communication, the paracrine factors are also responsible for tissue development, homeostasis and (re-)generation. The stem cell secretome consists of extracellular vesicles, specifically exosomes, microvesicles, membrane particles, peptides and small proteins (cytokines). The paracrine activity of stem cells, i.e. the stem cell secretome, has been found to be the predominant mechanism by which stem cell-based therapies mediate their effects in degenerative, auto-immune and/or inflammatory diseases. Though not only stem cells possess a secretome which influences their cellular environment, their secretome currently appears to be the most relevant for therapeutic use.

Hans Keirstead is a medical scientist and entrepreneur specializing in stem cell research.

Arnold Richard Kriegstein is a neurologist and neuroscientist at the University of California, San Francisco, where he served as director of the UCSF Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research from 2004 - 2021. His main research interests include neural stem cell and brain development. He is a member of the National Academy of Medicine.

<span class="mw-page-title-main">Shimon Slavin</span> Israeli professor of medicine

Shimon Slavin is an Israeli professor of medicine. Slavin pioneered the use of immunotherapy mediated by allogeneic donor lymphocytes and innovative methods for stem cell transplantation for the cure of hematological malignancies and solid tumors, and using hematopoietic stem cells for induction of transplantation tolerance to bone marrow and donor allografts.

<span class="mw-page-title-main">Edythe Broad</span> American art collector and philanthropist

Edythe Broad is an American art collector and philanthropist. Singly and with her husband Eli Broad (1933-2021), she has collected "about 2000 pieces of art valued at more than $2 billion" and supported arts initiatives such as the Los Angeles Opera and The Broad.

Thomas A. Rando is an American stem cell biologist and neurologist, best known for his research on basic mechanisms of stem cell biology and the biology of aging. He is the Director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research and a professor of Neurology and Molecular, Cell and Developmental Biology at the University of California, Los Angeles. Prior to joining the UCLA faculty, he served as Professor of Neurology and Neurological Sciences at Stanford University School of Medicine, where he was also founding director of the Glenn Center for the Biology of Aging. His additional roles while at Stanford included co-founder and deputy director of the Stanford Center on Longevity, founding director of Stanford's Muscular Dystrophy Association Clinic, and Chief of Neurology at the VA Palo Alto Health Care System.

<span class="mw-page-title-main">2020 California Proposition 14</span> Citizen-initiated ballot measure

California Proposition 14 is a citizen-initiated ballot measure that appeared on the ballot in the 2020 California elections, for November 3, 2020. It authorizes state bonds to be issued worth $5.5 billion, which will fund the California Institute for Regenerative Medicine (CIRM), which serves as the state's center for stem cell research, and enable it to continue its operations. This measure passed with 51% of the vote.

Regenerative Medicine Advanced Therapy (RMAT) is a designation given by the Food and Drug Administration to drug candidates intended to treat serious or life-threatening conditions under the 21st Century Cures Act. A RMAT designation allows for accelerated approval based surrogate or intermediate endpoints.

Maria Grazia Roncarolo is an Italian pediatrician who is currently George D. Smith Professor in Stem Cell and Regenerative Medicine and Professor of Medicine at Stanford University. She is also the Director of the Stanford Institute of Stem Cell Biology and Regenerative Medicine along with Irving Weissman and Michael Longaker and the Director for Center for Definitive and Curative Medicine at Stanford.

OTL-103 (GSK-2696275) is a gene therapy for Wiskott–Aldrich syndrome, a rare primary immunodeficiency caused by mutations in the gene that codes for Wiskott–Aldrich syndrome protein (WASp). It was developed by Orchard Therapeutics in conjunction with GlaxoSmithKline. It is currently undergoing Phase I/II of clinical trials that are expected to conclude in October 2025.

References

  1. ↑ "A Pragmatist, UCLA's Chancellor Runs Into Protests and PoliticsAlbert Carnesale". The Chronicle of Higher Education. 1998-12-18. Retrieved 2018-03-12.
  2. ↑ "The Carnesale Legacy". UCLA. Retrieved 2024-04-01.
  3. ↑ "Judith C. Gasson, Ph.D. – CIRM" . Retrieved 2024-04-01.
  4. ↑ Bloom, Stacie (2005-11-01). "UCLA director gets the goods as California makes good on its stem cell initiative". Journal of Clinical Investigation. 115 (11): 2958. doi:10.1172/JCI26988. ISSN   0021-9738. PMC   1265884 . PMID   16276406.
  5. ↑ Ornstein, Charles (2007-09-10). "UCLA to get $20-million gift for stem cell research". Los Angeles Times. Retrieved 2024-04-01.
  6. ↑ "UCLA and UCI awarded $8 million grant to launch collaborative stem cell clinic". UCLA. Retrieved 2024-04-01.
  7. ↑ "Alpha Stem Cell Clinics Network Expansion – CIRM". CIRM. Retrieved 8 April 2024.
  8. ↑ "Shared Resources Consortium". Research & Creative Activities. 2018-09-04. Retrieved 2024-04-01.
  9. ↑ "UCLA Training Program in Stem Cell Biology – CIRM" . Retrieved 2024-04-01.
  10. ↑ "Milestones | UCLA BSCRC". stemcell.ucla.edu.
  11. ↑ Lowry, W. E.; Richter, L.; Yachechko, R.; Pyle, A. D.; Tchieu, J.; Sridharan, R.; Clark, A. T.; Plath, K. (2008-02-26). "Generation of human induced pluripotent stem cells from dermal fibroblasts". Proceedings of the National Academy of Sciences of the United States of America. 105 (8): 2883–2888. Bibcode:2008PNAS..105.2883L. doi: 10.1073/pnas.0711983105 . ISSN   1091-6490. PMC   2268554 . PMID   18287077.
  12. ↑ Kohn, Donald B.; Booth, Claire; Kang, Elizabeth M.; Pai, Sung-Yun; Shaw, Kit L.; Santilli, Giorgia; Armant, Myriam; Buckland, Karen F.; Choi, Uimook; De Ravin, Suk See; Dorsey, Morna J.; Kuo, Caroline Y.; Leon-Rico, Diego; Rivat, Christine; Izotova, Natalia (2020). "Lentiviral gene therapy for X-linked chronic granulomatous disease". Nature Medicine. 26 (2): 200–206. doi:10.1038/s41591-019-0735-5. ISSN   1546-170X. PMC   7115833 . PMID   31988463.
  13. ↑ Kohn, Donald B.; Booth, Claire; Shaw, Kit L.; Xu-Bayford, Jinhua; Garabedian, Elizabeth; Trevisan, Valentina; Carbonaro-Sarracino, Denise A.; Soni, Kajal; Terrazas, Dayna; Snell, Katie; Ikeda, Alan; Leon-Rico, Diego; Moore, Theodore B.; Buckland, Karen F.; Shah, Ami J. (2021-05-27). "Autologous Ex Vivo Lentiviral Gene Therapy for Adenosine Deaminase Deficiency". The New England Journal of Medicine. 384 (21): 2002–2013. doi:10.1056/NEJMoa2027675. ISSN   1533-4406. PMC   8240285 . PMID   33974366.
  14. ↑ "UCLA builds on history of success developing novel immunotherapies to treat cancer". www.uclahealth.org. Retrieved 2024-04-01.
  15. ↑ Deng, Sophie (2023-12-05). Safety and Feasibility of Cultivated Autologous Limbal Stem Cells (cLSC) for Limbal Stem Cell Deficiency (Report). clinicaltrials.gov.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.